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doi:10.1016/j.ejvs.2010.05.005Abstract Objectives: To briefly inform on the conclusions from a conference on the next 10
years in the management of peripheral artery disease (PAD).
Design of the Conference: International participation, invited presentations and open discus-
sion were based on the following issues: Why is PAD under-recognised? Health economic impact
of PAD; funding of PAD research; changes of treatment options? Aspects on clinical trials and
regulatory views; and the role of guidelines.
Results and Conclusions: A relative lack of knowledge about cardiovascular risk and optimal
management of PAD patients exists not only among the public, but also in parts of the
health-care system. Specialists are required to act for improved information.
More specific PAD research is needed for risk management and to apply the best possible
evaluation of evidence for treatment strategies. Better strategies for funding are required
based on, for example, public/private initiatives.
The proportion of endovascular treatments is steadily increasing, more frequently based on
observational studies than on randomised controlled trials. The role of guidelines is therefore
important to guide the profession in the assessment of most relevant treatment.
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376 L. Norgren et al.Current data unambiguously document that peripheral coding for this disease, and national coding systems are notartery disease (PAD) is under-recognised by physicians,
allied health-care professionals and by the public. More-
over, it is suboptimally treated compared with other clin-
ical manifestations of atherosclerosis. From this statement,
a public health mandate arises to determine causes of this
health disparity and to determine what can be done in the
next 10 years to resolve these critical issues and improve
the prognosis and quality of life for PAD patients.
‘PAD 2009’ represents a collaboration platform between
the United Kingdom, Sweden, Switzerland and North
America, known as ‘Trans-Atlantic Vascular Medi-
cine’(TAVM, Fig. 1) that addressed these questions.Why is PAD Under-Recognised Compared with
Other Cardiovascular Diseases?
Current data from the United States and Canada demon-
strate that only 25% of the public, defined in population-
based surveys as adults over 50 who are ‘at risk’, know about
PAD, in contrast to the half to three-quarters of the identical
‘at risk’ populationwho know about coronary artery disorder
(CAD) and cerebrovascular disorder (CVD).1,2 At least three
major reasons mandate far more aggressive efforts to ach-
ieve public awareness of PAD. First, PAD is the cardiovascular
disease associated with the greatest functional impairment,
and no individuals with PAD are now known to be truly
‘asymptomatic’, as they perform functionally poorer.3
Second, PAD is the most common cause of major amputa-
tion worldwide, from which quality of life is rarely re-ach-
ieved and adequate PAD treatment can avert this major
adverse outcome. Third, and anchoring the most critical
public health impact, individuals with PAD, regardless of
clinical presentation, suffer the highest rates of fatal and
non-fatal cardiovascular events.
Reasons for variation in detecting and treating PAD may
be that the vascular community takes no joint responsibility
for educating colleagues who are not always aware of PAD-
related serious health consequences.
While every primary-care clinician recognises the
inherent risk of chest pain or cerebral ischaemic symptoms,
this level of PAD awareness and its linking to a diagnostic and
treatment plan has generally been poorly achieved. Any
national population-based effort to decrease cardiovascular
events cannot be achieved unless each health-care provider
takes action to assure that smoking cessation, anti-platelet
treatment, diabetes and lipid control and hypertension
management be achieved in every individual with PAD
according to guidelines (American College of Cardiology
(ACC)/American Heart Association (AHA);4 TASC II (Inter-
Society Consensus for the Management of Peripheral Artery
Disease);5 Scottish Intercollegiate Guidelines Network
(SIGN)6 and Canadian PAD Guideline2). To inform the public,
initiatives such as TARGET PAD Strategies (UK) are impor-
tant7 as is the PAD Coalition in the USA8 and Europe.The Health Economic Impact of PAD
The estimation of costs for the diagnosis and management
of PAD is difficult as there is no common internationalas concise as for CAD and CVD syndromes. Recently, it has
been determined that the annual direct health economic
cost of PAD in the United States is comparable to that of
heart failure, stroke, atrial fibrillation and other more
recognised cardiovascular syndromes,9 but this estimate is
known to be a minimal cost boundary as it did not include
individuals less than 65 years of age. Neither were indirect
costs or associated costs of heart attack and stroke in this
population included. The estimated total costs of PAD in
the United States exceeds $21 billion annually.10 Medicare
figures also demonstrate that the annual medical cost per
PAD patient is at least 5% higher than the cost per patient
with CAD. Complications after PAD treatment increase the
cost considerably.11 An important issue is whether
screening by ankleebrachial index (ABI) determination is
cost-effective. Some national agencies remain sceptical to
ABI screening of targeted high-risk populations12 and
further interventional studies are needed, although any
clinical trial to prove the value is unlikely as consensus in
favour of ABI use is uniform.
In case of disability due to restriction in ambulation, the
costs are considerably greater. This requires a view from
societal impact, including loss of wages and impact on the
family infrastructure, always considering the source of
funds to pay for this aspect of care associated with PAD.PAD Research: Who will Pay in the Future?
Strategies to secure funding for PAD research are likely to
be limited to local opportunities, particularly if the public
is unaware of the impact of the disease on life and limb.
While basic research is usually well supported by govern-
ment funding, translational clinical research is not. Thus,
although major advances in the diagnosis and treatment of
CAD have been achieved by large international clinical
trials of diagnostic and treatment strategies, no such clin-
ical trials of PAD populations have yet been initiated.
In distinct contrast to the health gains for individuals
with CAD, comparable advances have not been achieved for
patients with PAD. It is unclear whether this slow progress is
due to the smaller investment in clinical research by
governmental agencies and the pharmaceutical industry.
Case series and non-controlled or underpowered trials have
served as the hallmark of PAD clinical investigations. Data
contrasting the burden of disease, health-care costs and
research funding should be generated to inform policy-
makers. European or national surveys usually group
together all cardiovascular diseases, thus obscuring the
specific needs for PAD studies.13
Clinical research funding systems differ between coun-
tries, but a common mission exists, as represented by the
Medical Research CouncileNational Institute of Health
Research, UK (MCR-NIHR) and the National Heart, Lung and
Blood Institute, USA (NHLBI), to promote a dialogue with
the public about medical research, which may be of value
in increasing funding for PAD research.
Comparisons between effectiveness of various types of
treatment are of importance, currently initiated in the
USA. Both the Cardiovascular Outcomes for Renal Athero-
sclerotic Lesions (CORAL)14 and (CLaudication Exercise vs.
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underway to test current treatment strategies. Of interest,
the Institute of Medicine in the USA has listed PAD as
amongst the top 25% most-pressing clinical needs for
national comparative effectiveness research.16
In an era of global cost constraints, the most reason-
able way to increase PAD research funding might be the
creation of publiceprivate partnerships, including
industry and governmental sources. An example is Private
Public Partnership in Europe, although this consortium has
not yet included any PAD research. The academiae
industry relationship serves as an extremely promising
arena, but symposium participants noted that there is
a tangible risk of conflicts of interest (e.g., competing
recruitment for government vs. industry trials), an
unfortunate situation that may reduce important inter-
action and collaboration. One potential pathway to avoid
such conflicts and to foster investigational efficiency
would be for government to co-create PAD research
networks. Industry would be expected to support, with
financial and ‘in kind’ resources, the creation of such
networks, and would then likely benefit from shortened
drug and device development timelines.Will the Treatment Paradigm Shift?
When evaluating drug treatment for critical limb ischaemia
(CLI), end points should be realistic. At present amputa-
tion-free survival is the common primary end point in RCT,
with pain-relief and ulcer-healing as secondary end points.
Based on the fact that 20% of CLI patients die within a year
after the diagnosis was established,5 any optimally effec-
tive drug or biologic therapy should preferably act on both
prevention of serious cardiovascular events and on PAD limb
end points. Currently, there are no new recommendations
for drug treatment in CLI, with the exception that thera-
peutic angiogenesis renders some hope to improve ulcer
healing and reduce amputation rates.
Larger studies on various vascular growth factors such as
non-viral 1 fibroblast growth factor (FGF) and hepatocyte
growth factor (HGF), gene-therapy as well as stem-cell
therapy are underway. Many questions remain unresolved,
including the optimal delivery route, dosing, the long-term
outcome and relative safety, etc.17e19
Few medications are available to treat claudication
symptoms. The clinical benefit of cilostazol is estab-
lished,20 and new drugs may be expected to act directly on
muscle metabolism. Further evaluation of the role of sta-
tins in claudication is required.21
Endovascular therapy is the most significant advance in
the management of PAD, and the device evolution has
prompted many physicians to consider more liberal indi-
cations. A limitation for the endovascular approach is the
need for repeated interventions, and re-do procedures
whether endovascular therapy will ever provide a cost-
effective treatment for PAD relates to the expected
outcomes, durable improvement of quality of life in inter-
mittent claudication and wound healing and limb salvage in
CLI,22 compared with treatment alternatives (supervised
exercise training for intermittent claudication and surgery
for CLI) and to reimbursement systems.For patients with intermittent claudication it was
shown that improvement in walking distance and quality
of life is similar or, at best, has a moderate adjuvant
benefit in favour of endovascular therapy as compared
with supervised exercise training,23 but at higher mean
cumulative costs per patients for endovascular
therapy.24,25 Nevertheless, the acceptance of supervised
exercise training by physicians is limited due to the lack of
reimbursement by health-care payers and by patients, as
they have to invest time before reaping any health
reward. The situation is different when evaluating costs of
managing limb-threatening ischaemia. Here, the former
therapeutic gold standard of open surgery cannot
compare with endovascular therapy regarding early costs
in most series26,27 as patients have to spend more days in
hospital, suffer higher serious complication rates, with
higher initial cost of open surgery.28 It is, however,
important to note that outcome after endovascular and
open repair is about the same.25
Considering all aspects of revascularisation, it seems
realistic to foresee an era where endovascular interventions
will be the first choice, followed by hybrid procedures.
In complicated multi-segmental disease, however,
bypass surgery may remain the first choice.Regulatory Aspects
The important issue in the regulatory approval of new
therapies is the balance of risk versus benefit. Clinically
relevant criteria for the primary end point in CLI are
required, not only amputation-free survival, but also
complete healing of ischaemic ulcers and complete relief
of pain off narcotics. A response-based concept: the
patient being alive, keeping both legs, no wound or pain
and off analgesics may be reasonable as stated at the
Trans-Atlantic Conference PAD Trial Guidelines.29 The
safety issue needs further development; harm must be
avoided, but has to be related to efficacy. Risk manage-
ment planning for new approved drugs is of increasing
importance, aiming at ensuring that benefits of a drug or
another treatment exceed the risk by the greatest
achievable margin for the individual patient and for the
population as a whole.
Whether the commonly used primary end-point follow-up
period of 12months is sufficient, is doubtful. Ideally, patients
should be studied for 2 years to evaluate late effects. More
specific requirements to deal with efficacy and safety may
imply that the present phase system (phases I, II, III and IV)
will be outdated and replaced in due time.
In trials of intermittent claudication, the question
arises, whether to use initial claudication distance (ICD)
or absolute claudication distance (ACD) as the primary
end point. From the patient point of view, ICD is more
accepted and also clinically more important, while ACD
has a better reproducibility and has to be measured with
graded treadmill testing. At present, Europe employs
walking distance as a measure, and North America, peak
walking time. This makes comparisons of studies difficult.
Consensus has to be reached for a common design of new
trials. Quality-of-life measures must be integrated into
the assessment of any new treatment modality, which
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instruments.Figure 1 TransAtlantic Vascular Medicine (TAVM) activities
1994-2009.Clinical Trials
In general, new trials should compare the outcome for
patients, rather than vascular lesions, to present the best
advice to the PAD patients. Most importantly, PAD trials
have to include female and male subjects in relation to
their proportion in the population, and trials on secondary
preventions must include PAD patients in general and
specifically also asymptomatic individuals. A major chal-
lenge is, however, to recruit patients to participate in
trials. Reasons for poor recruitment in phase IV trials may
be that patients are using the study drug off-label, and in
phase III studies, lack of interest from referring physicians
slowing down enrolment, or unwilling patients, not
uncommonly due to lack of relevant information. It also has
to be taken into account that CLI patients are frequently
old and fragile. To increase recruitment, the first step must
be to provide appropriate information to all involved, which
should include common messages consistent with existing
guidelines. In principle, vascular centres of excellence
should invite each patient to a clinical trial to establish the
important culture of active participation in clinical
research.Are Guidelines Valuable?
For PAD, lessons can be gleaned from the successes and
challenges that have arisen in other guideline-driven
health-care arenas. For example, when organisations
produce differing recommendations, confusion regarding
treatment goals can overwhelm efforts to achieve even
the minimal expectations. Guidelines for the management
of risk factors for atherosclerosis exist not only from
various organisations,4e6 but also from several other
sources. As an example, in the UK, the Joint British Soci-
eties Guidelines, National Institute for Health and Clinical
Excellence (NICE), European Society of Cardiology
Guidelines as well as local hospital trust and primary-care
trust guidelines are available. The variations in some
recommendations, such as the target blood pressure level
and the use of statins, might be avoided by additional
consensus-driven collaboration. In this manner, efforts to
unify treatment messages based on the level of evidence
are likely to achieve greater success. Guidelines also have
to be endorsed without controversy and must be adopted
by the leaders.
Over the past 15 years, the evidence base that supports
the public health importance of PAD has increased consid-
erably. Past TAVM-conferences have led to the creation of
new PAD clinical investigations, new evidence-based PAD
practice guidelines (Fig. 1) and to public health focussed
non-profit awareness initiatives. Tools can now be
employed to achieve measurable improvements in PAD
public health. Yet, these improvements cannot occur
merely by the advocacy of vascular specialists. The true
stakeholders for improved PAD-related health include
government, professional medical societies (primary care,cardiovascular and others), payers and patient advocacy
groups.
All have to realise the three goals for PAD patients e to
reduce the risk of cardiovascular events, to reduce the risk
of amputation in CLI and to improve limb function.
To summarise, the PAD 2009 conference came to the
following conclusions:
 Data on prevalence, management and outcomes of PAD
are not well recognised by primary health care, the
public and governmental authorities. PAD is, therefore,
under-diagnosed and under-treated. Strong efforts are
required to change this pattern, for example, through
‘PAD coalitions’ and the media.
 Assessment of cost-effectiveness in the management of
PAD is difficult due to variation in coding and reluctance
to specify PAD in patients with more evident athero-
sclerotic symptoms, CAD and CVD. More specific PAD
coding is needed, requiring involvement of the vascular
societies internationally and nationally.
 There is a great need for PAD research, but funding
strategy is uncommon Public/private initiatives are
important and collaboration on all levels required.
Increased public awareness of PAD may be helpful in
this respect.
 Although therapeutic angiogenesis may be of value for
a proportion of CLI patients, no real breakthrough is
expected in the medical treatment of PAD within the
next 10 years. Endovascular therapy remains the major
advance in the management of the PAD patient and will
further replace open surgery. Hybrid procedures are
expected to increase.
 In the development and assessment of new treatments,
focus has to be directed more on safety and efficacy for
the single patient that requires longer follow-up
periods than commonly used.
 PAD trials should include the prevalence-related
proportion of women and asymptomatic subjects.
 Vascular clinical care guidelines will be most effective
when consensus is maximal, recommendations are pri-
oritised, and dissemination plans are created, funded
and used.
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Addendum
‘PAD2009’ as part of the Trans Atlantic Vascular Medicine
collaboration was held in O¨rebro, Sweden, 12e13 May 2009,
to discuss what needs to be done during the next 10 years to
achieve better risk management and symptomatic treat-
ment in PAD patients. The 2-day meeting included main
topics related to the sub-headings of this article. Speakers
were invited from Europe and North America, representing
the medical profession, regulatory authorities and funding
organisations.
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